GLP-1 Agonist
Semaglutide
Long-Acting GLP-1 Receptor Agonist
Semaglutide is a 94% homologous analogue of native GLP-1 with C-18 fatty acid chain modification enabling albumin binding and extended half-life of approximately 7 days. Approved clinically as Ozempic and Wegovy, it represents the gold-standard GLP-1 agonist research compound for comparative metabolic studies.
Quantity
5MG
Purity
98%+
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION
Research Information
- Long-acting GLP-1 analogue with ~7-day half-life via albumin binding mechanism
- 94% sequence homology to native GLP-1 with fatty acid chain modification
- Approved clinical compound — highest evidence base among GLP-1 research tools
- Studied across metabolic, cardiovascular, renal, and neuroendocrine research paradigms
- Key reference compound for comparing novel incretin receptor agonists
Storage Conditions
- Long-term: −20°C lyophilised
- Reconstituted: 4°C, use within 4 weeks
- Avoid freeze-thaw cycles
Safe Handling
- For laboratory research use only
- Handle with appropriate PPE
Frequently Asked
COMPOUND FAQ
Continue Exploring
RELATED COMPOUNDS
Triple Receptor Agonist
Retatrutide
A next-generation triple incretin receptor agonist demonstrating potent multi-receptor activity in preclinical research models.
Reconstitution Solution
BAC Water
Sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative. The standard reconstitution vehicle for research peptide compounds.
COMING SOON
Dual Receptor Agonist
Tirzepatide
A synthetic dual incretin receptor agonist targeting both GLP-1 and GIP receptors, representing the current clinical benchmark for metabolic research and glycaemic regulation studies.
RESEARCH USE ONLY: Semaglutide is sold exclusively for in vitro laboratory research. Not intended for human or animal consumption. Not for clinical or therapeutic use.